Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc.(BIO.B)股票分析

$365.080

0.000 (0.00%)收盤時

Loading chart…
High
365.080
Open
399.980
VWAP
Vol
0.00
Mkt Cap
Low
365.080
Amount
0.00
EV/EBITDA, TTM
22.58

Bio-Rad Laboratories, Inc. is engaged in developing, manufacturing, and marketing a range of products for the life science research and clinical diagnostics markets. The Company offers a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. It operates through two segments: Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used for biological research, biopharmaceutical production processes, food testing regimes, and science education. Its Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. These products are sold to hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories.

AI analysis of Bio-Rad Laboratories, Inc. (BIO.B)

buy

Bio-Rad Laboratories Inc is a good buy right now due to its strong recent performance, with a 20-day change of +18.01% and a current price of 365.08, which is significantly above its 200-day simple moving average of 299.542. Additionally, the stock has a high RSI of 99.938, indicating strong momentum. However, the main risk is the negative earnings per share (EPS) of -19.55 reported in Q1 2026, which could impact investor sentiment.

估值指標

The current forward P/E ratio for Bio-Rad Laboratories, Inc. (BIO.B) is 40.00, compared to its 5-year average forward P/E of 30.68.

Forward P/E

Strongly Overvalued
5Y Average P/E
30.68
Current P/E
40.00
高估
33.90
低估
27.47

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
19.95
Current EV/EBITDA
22.58
高估
27.28
低估
12.61

Forward P/S

Overvalued
5Y Average P/S
3.14
Current P/S
3.71
高估
3.49
低估
2.78

Alphio AI Price Scenarios for BIO.B

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%BIO.B

$267.26

情境價格

B

Base

Base · 50%BIO.B

$242.13

情境價格

B

Bear

Bear · 25%BIO.B

$195.00

情境價格

事件時間軸

2025-08-01 (ET)

10:00:09

Bio-Rad rises 15.8%

2025-07-31 (ET)

16:28:26

Bio-Rad sees FY25 non-GAAP, currency-neutral revenue growth of flat to up 1%

16:27:21

Bio-Rad reports Q2 adjusted EPS $2.61, consensus $1.75

2025-07-07 (ET)

09:23:59

Bio-Rad expands digital PCR offering with new platforms

2025-05-01 (ET)

16:26:34

Bio-Rad now sees non-GAAP revenue for FY down 1% to up 1.5%

資訊

BIO.B FAQ — answered by Alphio AI

Bio-Rad Laboratories, Inc. is engaged in developing, manufacturing, and marketing a range of products for the life science research and clinical diagnostics markets. The Company offers a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. It operates through two segments: Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used for biological research, biopharmaceutical production processes, food testing regimes, and science education. Its Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. These products are sold to hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories. It operates in the Healthcare sector.

Bio-Rad Laboratories Inc is a good buy right now due to its strong recent performance, with a 20-day change of +18.01% and a current price of 365.08, which is significantly above its 200-day simple moving average of 299.542. Additionally, the stock has a high RSI of 99.938, indicating strong momentum. However, the main risk is the negative earnings per share (EPS) of -19.55 reported in Q1 2026, which could impact investor sentiment.

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

免費開始